Pharmaceutical Manufacturing in Taiwan

Mds Pharma Services

MDS Pharma Services – The world's premier provider of innovative drug discovery and development solutions. We offer a full spectrum of world-class discovery, preclinical and clinical resources and expertise, strategically located around the world, to meet the needs of the global pharmaceutical and biotech industries. Our broad range of services is designed to increase the speed, precision and productivity of your drug discovery and development activities. Through 2009 and 2010, MDS Inc. divested the assets of MDS Pharma Services- The former discovery and preclinical businesses (Pharmacology/DMPK and Drug Safety Assessment) have been acquired by Ricerca Biosciences LLC- The former early stage clinical research operations (the Development & Regulatory Services consultancy and Early Stage Development business) have been acquired by Celerion Inc- The former late stage clinical research operations (Global Clinical Development) have been acquired by INC Research- The former clinical laboratory operations (Global Clinical Development) have been acquired by Clearstone Central Laboratories.

1001 to 5000 staff

Formosa Laboratories, Inc

Formosa Laboratories, Inc. produces APIs and UV-filters in its modern facilities near Taipei. Its GMP compliance has been approved by DOH of Taiwan, US FDA, BGV of Germany, EDQM and PMDA of Japan. Formosa’s major API products include Vitamin D derivatives (Alfacalcidol, Calcitriol, Calcipotriol, Doxercalciferol, and Paricalcitol), Balsalazide, Benzonatate, Capsaicin, Colesevelam, Gadodiamide, Flupentixol, Melitracen, Meprobamate, Montelukast, Mycophenolate Mofetil, Sevelamer (HCl and Carbonate), and Taltirelin. As a major producer in the world, our UV-filter products include avobenzone and Octinoxate. We also provide custom synthesis service from process development to full commercial production for APIs and other specialty chemicals, with full documentation support.

501 to 1000 staff

Panion & Bf Biotech Inc

Panion & Bf Biotech Inc is a company based in Taiwan. Welcome to join PBF private product demostration group at

501 to 1000 staff

Qps Holdings, Llc

QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. We are passionate about our work, creating value for patients and customers while generating opportunities for employees to thrive. Since 1995, it has rapidly expanded from a tiny bioanalysis shop to a full-service CRO with 1100+ employees in the US, Europe, India and Asia. Today, it offers expanded pharmaceutical contract R&D services with special expertise in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Clinical Development. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to deliver superior quality, skilled performance and trusted service to its valued customers.

1001 to 5000 staff

Astrazeneca Taiwan

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

501 to 1000 staff

Anya Biopharm Inc

Anya is a young, agile and innovative publicly listed (TWO: pharmaceutical company founded in Taipei, Taiwan. We started with our flagship program #miraje in late 2016 with our oral peptide delivery platform, currently at clinical stage. The founding team comes with average 15 years of mid-senior level experience in General Management, Business Development and Regulatory Affairs functions at leading generic companies as Sandoz, Alvogen, Biocon and Zydus. Our guiding principles are 3Es - Excellence, Engagement and Efficiency. We also offer consulting services on Market Expansion, Portfolio Development and Business Development services to global companies to establish business and partnerships is Taiwan, Kore and China and offering companies from the region to expand in to US, EU and RoW Markets.

1 to 10 staff

Bora Pharmaceuticals

Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in complex oral solid dose, liquids, semi-solids, opthalmics, biologics, and sterile injectable products. We provide early phase clinical through to commercial manufacturing with full packaging capabilities to biopharma companies worldwide. Bora owns and operates in ten state-of-the-art CGMP manufacturing facilities across Asia and North America – delivering to more than 100 markets around the world. Our sites have the highest international standards for manufacturing, packaging, R&D and analytical testing. As a future focused CDMO, we know better than most that our own success is shaped by our partners victories. That's why, when you choose Bora - we make success more certain by following Bora’s 5Ps – Promises, Partnerships, Pride, People, and Progress. These 5 principles are Bora’s Pledge to our customers. Follow us to find out more and keep up to date with Bora Pharmaceuticals.

1001 to 5000 staff

Innopharmax, Inc

INNOPHARMAX develops oral new dosage form new drugs for further clinical development and commercialization, utilizing core drug delivery technology platforms OralPAS®, OralPAS Pro®, and MUCR. We are committed to improve the safety and efficacy of currently available drugs, and provide superior and cost effective medical options.

11 to 50 staff

Tsh Biopharm Corporation Ltd

TSH Biopharm starts in the field of chronic diseases and adheres to the principles of integrity and honesty. With a focus on innovation and excellence, our mission is to provide superior healthcare services for all stages of patient care. Our core products are centered around "patient-centric" treatments, including cardiovascular medications, gastrointestinal medications, and central nervous system medications. We cultivate the niche market of chronic diseases while simultaneously pursuing a dual-engine strategy to pioneer precision medicine and offer comprehensive treatment options. For more information, please visit

51 to 200 staff

Allgenesis Biotherapeutics Inc

Allgenesis is a privately-held, clinical stage ophthalmology company based in Taiwan. The company is focused on novel multi-specific fusion proteins for treating diabetic macular edema and wet-age-related macular degeneration; and small molecule eye drops for dry eye and pterygium diseases.

11 to 50 staff

Efficient Pharma Management Corp

Efficient Pharma Management Corp.(EffPha) provides drug development services for pharmaceutical companies. Our services focus on information integration for the submission package preparation, strategic planning, and efficient management of the clinical study to accelerate your drug development to approval. With extensive regulatory experience and multi-cultural familiarity, EffPha serves as your regional hub in Asia, and bridges the gaps between Asian and global pharmaceutical industries to widen your market reach.

11 to 50 staff

Msd Taiwan

201 to 500 staff

Reber Genetics Co., Ltd

Reber Genetics was founded in 2008 with the objective of becoming a successful biotechnology company devoted to innovative R&D and high-quality products. The mission of Reber Genetics is to deliver preventative health care in animals. To achieve that, we concentrate on the development of highly efficacious, safe animal vaccines. Now we are expanding the product pipeline and aim to bring these innovative vaccine products onto the global markets. We are proud to be the frontrunner in applying state of the art technologies to animal vaccines and we are confident in our ability to create the best solutions for our customers.

51 to 200 staff

Scivision Biotech Inc

SciVision Biotech Inc, founded in 2001, is now a public company listed at Taiwan Stock Exchang (Stock symbol : 1786) SciVision Biotech Inc. manufactures Hyaluronic acid products by using own-developed Cross-linked Hyaluronic Acid Platform (CHAP) to make the characteristics of Hyaluronic acid products be precisely controllable, and can be widely used in the production of cross-linked Hyaluronic acid products with different types and physical properties. The technology of Cross-linked Hyaluronic Acid Platform (CHAP) established the leading position of SciVision Biotech Inc. in the field of medical grade Hyaluronic acid products. The population structures of both developed and developing countries are gradually moving towards an aging society. The pursuit of beauty and health, as well as the demand for medical care of degenerative diseases has increased day by day. The main products of our company are Hyaluronic acid dermal fillers (for medical and cosmetic surgical use), Hyaluronic acid anti-adhesion gels (for surgical use) and Hyaluronic acid viscosupplement (for treatment of knee osteoarthritis). The three Hyaluronic acid products are high-evel medical devices that cater to the commercial possibilities for next 10-year growth. Today, our company has gradually increased the technology scale and is being devoted to the health and beauty fields, to create a better vision and reach the human’s aesthetic realm SciVision Biotech acquired a nearly square meter site located in Kaohsiung Cianjhen Technology Industrial Park for the construction of a new manufacturing facility to accommodate the growing production needs. The facility was GMP certified, and was constructed based on FDA standard, fully equipped with advanced automatic equipment. We work with pharmaceutical and specialty companies worldwide to develop long-term competitiveness. SciVision’s vision is to contribute its accumulated technologies and experience for the benefit of all humankind.

51 to 200 staff

Taiwan Bio-Manufacturing Corporation

Taiwan Bio-Manufacturing Corporation (TBMC), conceived by the Ministry of Economic Affairs and jointly established by the Industrial Technology Research Institute (ITRI) and the Development Center for Biotechnology (DCB), officially commenced operations in May 2023. Dedicated to advancing biomanufacturing capabilities, TBMC partners with National Resilience, Inc.(Resilience), a technology-focused biomanufacturing company. Combining the expertise of National Resilience Inc. and Taiwan’s smart manufacturing capabilities, TBMC is dedicated to developing state-of-the-art solutions for the production of complex medicines, including (i)mRNA drug,(ii)viral therapy, and (iv)CHO-C protein pharmaceutical platforms.

51 to 200 staff

Taiwan Biotech Co., Ltd

Founded in 1945, Taiwan Biotech (TBC) is the first local pharmaceutical company in Taiwan. We have devoted over 75 years to developing and supplying superior generic drugs that cover a variety of therapeutic areas. TBC has established international business and development division since 1996 to promote the products globally and nurtured a stable and continuously-growing sales network across Japan, Southeast Asia, Mainland China, and North America. We strive to innovate and will continue expanding our global footprint.

1001 to 5000 staff

Tty Biopharm Company Limited

TTY Biopharm Co, Ltd. was established on July 22nd 1960. TTY is a Taiwan's leading pharmaceutical manufacturing company which specializes in the development of special formulations and new drugs. TTY focuses on research & development and innovation of antitumor and against severe infection's areas. We will continue to develop in healthcare product portfolio to support the physicians and patients with completed approach to disease treatment. In product development, we continuously build win-win business relationships with partners through innovation derived from our successful “specialty sustained release technology platform”, and continuously enhance our production quality and efficiency through designing customized production protocol. In manufacturing, TTY owns internationalized factories with high-standard quality controlling process and excellent production management. Our manufacturing base was established according to international standards, and it is able to produce drugs of high competitive barriers and added values for global marketing. In marketing, TTY uses the foundation of solid research and development and production capabilities to build global strategic alliances. It also uses self-owned sales teams and company of joint venture to expand markets. TTY now is an innovative,"global marketing and drug development oriented" innovative biotech enterprise. By the incessant improvement in product development, manufacturing and marketing, TTY strives to become the world leading pharmaceutical company specialized in developing and marketing specialty formulation products and biologics.

501 to 1000 staff

Anxo Pharmaceutical Taiwan Co. Ltd

Anxo Pharmaceutical Co. was founded in 2003, we are a technology based specialty pharmaceutical company aimed on development and manufacturing of all pharmaceutical products. Nowadays the environment of international pharmaceutical market and medical health insurance policy have been changed very quickly. In order to provide high quality medicine and advanced technology of pharmaceutical manufacture, ANXO has devoted to invest state of the art equipments, and to build up professional R&D teams dedicated to develop many critical technology platforms for high quality pharmaceutical products in the global market.

201 to 500 staff

Formosa Pharmaceuticals, Inc

Formosa Pharmaceuticals () is a clinical stage biopharmaceutical company with primary focus in ophthalmology and oncology. Our flagship asset, APP13007 (Clobetasol Propionate ophthalmic suspension 0.05%) was recently approved by the US FDA (March, 2024) for the treatment of post-operative inflammation and pain following ocular surgery. In August, 2017, Formosa Pharmaceuticals completed the acquisition of Activus Pharma, based in Funabashi, Japan. With the acquisition of the Activus Pure Nanoparticle Technology (APNT) Platform, Formosa Pharmaceuticals enters the ophthalmology disease area with two late-preclinical assets and the goal of expanding the platform’s scope and application. APNT effectively reduces API particle size to improve dissolution and bioavailability without the drawbacks of heavy metal contamination other platforms often experience.

11 to 50 staff

Dfc - Dah Feng Capsule

Dah Feng Capsule (DFC) is the leading supplier of empty hard capsules in Taiwan. DFC provides safe and reliable empty hard capsules for pharmaceutical and nutraceutical industry, including acid-resistant vegetable capsules, general vegetable capsules and gelatin capsules.We are certified by PIC/S GMP, ISO 9001, and FSSC Established in 1967, DFC has continued to dedicate great efforts in achieving the highest customer satisfaction with over 50 years of experience in the industry. DFC has been the leading supplier of empty hard capsules to major pharmaceutical companies in Taiwan and prestigious nutraceutical producers in the US.

201 to 500 staff

Apple Biomedical

Apple BioMedical Inc. is an ISO13485 certified medical supplier with core competencies in the anatomical / pathological models and medical training devices. Building on 25 years of excellence, we aim to deliver precise and live-saving medical information to the public and to provide vivid visual representation for the world!

11 to 50 staff

Astracrux Clinical Trial And Consulting Inc

AstraCrux Clinical Trial and Consulting assists hospitals, pharmaceutical companies and CRO clients in finding prompt solutions to the legal obstacles involved in running clinical trials and conducting research. We can also offer quality medical science consulting, including product development strategies and clinical trial planning and design, as well as specialist training. Greater China and the Asia-Pacific are our main markets. However, we are also able to provide certain services in some parts of Europe, as well as the US. Our services for Clinical and drafting Clinical Site Agreements (CSAs)/ Clinical Trial Agreements (CTAs)-Review agreements required for clinical trials e.g. CDA, CSA/CTA, Key Opinion Leader Agreements, Service & Consulting Purchase Agreements, Licensing Agreement, Copyright Transfer Agreements & Material Transfer Agreements -Template preparation -Budget negotiations -Complete legal coverage via our international alliance network Consulting and Training Science Consulting -Training Services and Information Seminars Risk legal risk management plans -Helping to avoid, reduce & transfer legal risk -Ad hoc services for dealing with unexpected events Please see our homepage for more information.

11 to 50 staff

Jiantong Pharmaceuticals Ltd

Pharmaceutical company based in Taichung, Taiwan.

1 to 10 staff

Taron Solutions Limited

Taron Solutions Limited is a rising global contract translational, development, and manufacturing organization (CTDMO) with focus on cell/gene therapy and biologic drug products. Unlike traditional CDMOs, we love to provide solutions and we do not believe in a black box approach to projects. We work closely with clients to ensure that the project design makes sense within the time and budget and will meet all regulatory requirements to ensure right-the-first time. This means we will ensure frequent communication with our project management and scientific leads every step of the way. We specializes in the following: 1) Gene and cell line design and development 2) Upstream + downstream drug development 3) CMC study design and execution by QbD

11 to 50 staff